Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre V Hirayama

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Journal of Immunological Methods|December 31, 2020
Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistryJocelyn H Wright, Li-Ya Huang, Stephanie Weaver, et al.
Haematologica|June 19, 2025
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myelomaAndrew J Portuguese, Emily C Liang, Jennifer J Huang, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patientsDiego V Clé, Alexandre V Hirayama, Alvaro J Alencar, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemiaAdriana Seber, Claudio Galvão de CastroJunior, Lucila N Kerbauy, et al.
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
JCO Clinical Cancer Informatics|January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based ModelsEmily C Liang, Yein Jeon, Yang Qiao, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Blood Advances|January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinicRahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Journal of Immunological Methods|December 31, 2020
Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistryJocelyn H Wright, Li-Ya Huang, Stephanie Weaver, et al.
Haematologica|June 19, 2025
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myelomaAndrew J Portuguese, Emily C Liang, Jennifer J Huang, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patientsDiego V Clé, Alexandre V Hirayama, Alvaro J Alencar, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemiaAdriana Seber, Claudio Galvão de CastroJunior, Lucila N Kerbauy, et al.
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
JCO Clinical Cancer Informatics|January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based ModelsEmily C Liang, Yein Jeon, Yang Qiao, et al.
Pageof 4